MaxCyte IPO Presentation Deck

A Leading Provider of Cell-engineering Platform With 400+ platforms in place, our proprietary technology platform unlocks the significant potential of advanced therapeutics Leading the growing next- generation cell therapy market and capitalize on rising demand for non-viral engineering approaches • Enables delivery of almost any molecule into almost any cell type • Leads the industry in performance (measured by consistency, efficiency, viability, flexibility and scale) • Extensive product portfolio, supported by a robust intellectual property portfolio . -23% 5-year CAGR of organic revenue growth; pharmaceutical-level gross margins of -89% July 2021 20+ years of cell engineering expertise; 20+ field sales and application scientists that support our customers • Significant number of collaborations with industry and academia • Supported by our FDA Master File and International Technical Files to reduce clinical risk/shorten clinical development; referenced in over 30 clinical trials CONFIDENTIAL Innovative business model focused on value creation and shared partnership success • Allows MaxCyte to participate in the value created by our partners' programs • 13 Strategic Platform Licenses (SPLs), which include over $950m in potential pre- commercial milestone payments with upside from commercial sales-based payments • Focused over the long-term on creating a diverse portfolio of patient treatments for indications developed by our strategic partners

View entire presentation